

Mechanical Mitral Valve Thrombosis in a Patient with COVID-19 Infection

Emre Aruğaslan,¹ Yunus Çalapkulu,¹ Ender Örneç,¹ Mustafa Karanfil,¹ Hüseyin Bayram,² Seref Alp Küçükçer²

Departamento de Cardiologia, Hospital da Cidade de Ancara,¹ Ancara – Turkey

Departamento de Cirurgia Cardiovascular, Hospital da Cidade de Ancara,² Ancara – Turkey

Introduction

The novel coronavirus disease-2019 (COVID-19) caused by “Severe Acute Respiratory Syndrome Coronavirus-2” (SARS-CoV-2) became a global pandemic. Although respiratory involvement is the predominant presentation, current evidence has shown that COVID-19 is a multisystemic disease with coagulopathy and thromboembolic complications. Increased production of tissue factor and thrombin reduced fibrinolysis due to hyperinflammation are the proposed mechanisms of COVID-19 induced thrombosis.¹

We present a case of a COVID-19 infected patient with thrombosis of the mechanical mitral valve.

Case Report

A 46-year-old male patient who underwent mitral mechanical valve replacement 3 years ago was admitted with a 1 week history of mild dyspnea and malaise. Physical examination revealed the absence of prosthetic click. There was neither jugular venous distension nor rales on lung auscultation. The patient was hemodynamically stable. Electrocardiography showed sinus rhythm with nonspecific ST-segment changes. Regular medications consisted of only warfarin 5 mg/day. His recent medical history was remarkable due to the COVID-19 infection in his household. It was decided to test the patient for COVID-19 because of close contact and subfebrile fever (37.5 °C). Real-time polymerase chain reaction nasopharyngeal swab test was positive for SARS-CoV2. Chest computed tomography scan performed in the emergency department revealed bilateral centrilobular infiltrations, which were reported as atypical COVID-19. Transthoracic echocardiography (TTE) detected severely restricted leaflet mobility, with a mean transvalvular gradient of 23 mmHg (Figure 1). Obstructive thrombus with a 2.2 X 0.8 cm diameter extending to the left ventricular outflow tract was seen (Figure 1, Video 1). Fluoroscopy also showed restricted mobility of leaflets. Admission INR was 3.26. Medical records revealed monthly

therapeutic INR measurements before hospitalization. There was no other thrombotic episode in the patient’s past medical history. There was mild hypoxemia (PaO₂:71 mmHg) on arterial blood gas analysis. Initial laboratory tests showed levels of D dimer 1.0 mg/L (< 0.55), C- reactive protein 0.02708 g/L (0 - 0.005), IL-6 14.7 pg/mL (0 – 3.4), platelets 258 x 10⁹/L(150-400), and ferritin 58 µg/L (22 – 322). Blood cultures were obtained to rule out infective endocarditis. Emergent surgery was declined due to hemodynamic stability and active COVID-19 infection.

The patient was admitted to the intensive care unit to monitor symptoms and hemodynamics. Warfarin was stopped, and intravenous unfractionated heparin was administered with aPTT guided dosing. The patient was closely monitored for signs of heart failure and hemodynamic instability. On the third day of treatment, TTE showed decreased mitral valve gradients (mean 12 mmHg). Heparin treatment was continued. However, the patient deteriorated because of supraventricular tachycardia and subsequent pulmonary edema on day 7. Bedside echocardiography was done immediately and demonstrated re-elevation of the mean pressure gradient to 28 mmHg. Emergent thrombolytic was administered 10 mg bolus of tPA and 90 mg infusion in 90 minutes; however, no amelioration was seen in neither clinical nor echocardiographic parameters after lytics. Urgent mitral valve replacement was needed. Adherences from previous cardiac surgery were released after redo median sternotomy. Cardiopulmonary bypass was established with venous cannulation. Thrombosis was observed on the mechanical valve by the left atriotomy approach. The thrombosed mechanical valve was excised, and a new mechanical valve (29 mm, Sorin) was replaced. He was discharged with a target INR of 3.5 after uneventful postoperative care. As COVID-19 infection was supposed to be the trigger of mechanical valve thrombosis, no further hematological investigation was done. The patient has not experienced any adverse event after discharge.

Discussion

We described a case of mechanical mitral valve thrombosis in a COVID-19 patient. Thrombotic complications of the cardiovascular system are evident in the literature. There have been reports of venous thromboembolism and coronary artery thrombosis cases related to COVID-19.^{2,3} Bioprosthetic mitral valve thrombosis was successfully treated by the initiation of anticoagulation in an elderly patient with COVID-19.⁴ Guidelines recommend at least prophylactic dose of low molecular weight heparin for all hospitalized COVID-19 patients in the absence of absolute contraindications.¹

Mechanical heart valve thrombosis is a life-threatening complication necessitating prompt diagnosis and treatment.

Keywords

COVID-19/complications; Mitral Valvesurgery; Inflammation; Thrombosis; Blood Coagulation, Disorders/complications.

Mailing Address: Emre Aruğaslan •

Ankara Şehir Hastanesi Kardiyoloji Kliniği, Üniversiteler Mahallesi 1604. Cadde No: 9 Çankaya/Ankara - Turkey

Email: dremrearugaslan@gmail.com

Manuscript received July 08, 2021, revised manuscript October 08, 2021, accepted December 08, 2021

DOI: <https://doi.org/10.36660/abc.20210581>




Figure 1 – Echocardiographic images of obstructed mechanical valve.

It is usually associated with inadequate anticoagulation. TTE and transesophageal echocardiography (TEE) are essential for diagnosis and determining the degree and cause of valve dysfunction. TEE was not performed in this COVID-19 patient due to the heightened risk for SARS-Cov-2 spread. Cinefluoroscopic provides additional information about leaflet mobility and opening. Emergency valve replacement is recommended for obstructive prosthetic valve thrombosis in critically ill patients, but fibrinolysis should be considered if the surgical risk is high.⁵ Low risk of bleeding, involvement of the right valves, first episode of valve thrombosis, and thrombus smaller than 1 cm² are other factors that make fibrinolysis more favorable.⁶ Heart team decided to administer fibrinolytic due to concerns about perioperative hyperinflammation and hypercoagulability associated with COVID-19⁷ but redo surgery was eventually needed after thrombolytics failed.

COVID-19 infection has been associated with increased mortality in patients undergoing cardiac surgery.⁸ Exaggerated inflammatory response to the virus may augment the risk of acute respiratory distress syndrome (ARDS) postoperatively.⁹ A case of acute postoperative thrombosis of the aortic valve and subsequent coronary embolism was reported.¹⁰ The risk of perioperative transmission of the virus to health care personnel should also be kept in mind. However, delaying the surgery in a patient with prosthetic valve thrombosis is also risky due to complications such as cardiogenic shock, heart failure and systemic embolism. The decision between surgery and thrombolysis for mechanical valve thrombosis should be individualized. Clinical factors, local experience and surgical expertise are critical factors in the decision pathway.

Conclusions

Literature has consistent data regarding hypercoagulability in COVID-19 infection, so we presumed that Coronavirus disease was the predisposing factor in the development of mechanical valve thrombosis in a patient with therapeutic INR

values. However, it should be noted that thrombosis developed although proinflammatory markers were moderately elevated. Similarly, recurrent coronary thrombosis in a moderate case of COVID-19 was reported,² so hyper inflammation may not be the sole pathway leading to thrombosis in patients with COVID-19.

Physicians should be aware of thrombotic complications during this outbreak. Preventive and therapeutic use of antithrombotic drugs should be done in parallel to formal recommendations to mitigate the thrombotic burden in COVID-19 patients.¹

Author Contributions

Conception and design of the research: Bayram H, Küçükler SA; Acquisition of data: Arugaşlan E, Çalapkulu Y; Analysis and interpretation of the data: Karanfil M; Writing of the manuscript: Arugaşlan E, Karanfil M, Örnek E; Critical revision of the manuscript for intellectual content: Örnek E, Bayram H, Küçükler SA.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This study is not associated with any thesis or dissertation work.

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;75(25):2950–73. doi: 10.1016/j.jacc.2020.04.031.
2. Muguerza J, Loizeau PA. Recurrent coronary thrombotic events in a moderate case of COVID-19. *BMJ Case Rep*. 2021;14(1):e237624. doi: 10.1016/j.jacc.2020.04.031.
3. Scudiero F, Più A, Keim R, Parodi G. Acute pulmonary embolism in COVID-19 patient: a case report of free-floating right heart thrombus successfully treated with fibrinolysis. *Eur Heart J Case Rep* 2020;5(1):ytaa388. doi: 10.1093/ehjcr/ytaa388.
4. Llopis Gisbert G, Vidal Urrutia V, Moruno Benita MA, Payá Chaume A, Berenguer Jofresa A, Cubillos Arango AM et al. Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19. *Can J Cardiol*. 2021;37(6):938.e3-938.e6. doi: 10.1016/j.cjca.2020.10.008.
5. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2017;38(36):2739-91. doi: 10.1093/eurheartj/ehx391.
6. Tarasoutchi F, Montera MW, Ramos AIO, Sampaio RO, Rosa VEE, Accorsi TAD et al. Update of the Brazilian Guidelines for Valvular Heart Disease - 2020. *Arq Bras Cardiol*. 2020 Oct;115(4):720-75. doi: 10.36660/abc.20201047.
7. Günaydin S, Stammers AH. Perioperative management of COVID-19 patients undergoing cardiac surgery with cardiopulmonary bypass. *Perfusion*. 2020;3(6):465-73. doi: 10.1177/0267659120941341.
8. Sanders J, Akowuah E, Cooper J, Kirmani BH, Kanani M, Acharya M, et al. Cardiac surgery outcome during the COVID-19 pandemic: a retrospective review of the early experience in nine UK centers. *J Cardiothorac Surg*. 2021;16(1):43.
9. Mavioglu HL, Ünal EU, Aşkın G, Küçükler ŞA, Özatik MA. Perioperative planning for cardiovascular operations in the COVID-19 pandemic. *Turk Gogus Kalp Damar Cerrahisi Derg*. 2020;28(2):236-43. doi: 10.1186/s13019-021-01424-y.
10. Manghat NE, Hamilton MCK, Joshi NV, Vohra HA. Acute postoperative thrombosis of an aortic valve prosthesis and embolic myocardial infarction in a coronavirus disease 2019 (COVID-19)-positive patient-an unrecognised complication. *JTCVS Tech* 2020; 4:111-3. doi: 10.1016/j.xjtc.2020.09.020.

*Supplemental Materials

See the Supplemental Video, please click here.



This is an open-access article distributed under the terms of the Creative Commons Attribution License